
IQVIA Holdings Inc.
NYSE•IQV
CEO: Mr. Ari Bousbib
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2013-05-09
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Contact Information
Market Cap
$37.85B
P/E (TTM)
29.5
35.6
Dividend Yield
--
52W High
$234.30
52W Low
$134.65
52W Range
Rank35Top 21.9%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$4.10B+5.24%
4-Quarter Trend
EPS
$1.94+23.57%
4-Quarter Trend
FCF
$1.20B+110.33%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenues reached $11.95B USD for nine months, marking a 4.4% increase over prior year period.
Operating Cash Flow Rises Cash provided by operating activities totaled $1.92B USD for nine months, increasing $88M compared to 2024.
R&D Backlog Expansion Research & Development Solutions contracted backlog grew to $32.4B USD as of September 30, 2025, expecting $8.1B conversion soon.
Debt Issuance Completed Issued $2.0B in 6.250% Senior Notes due 2032 to repay revolving credit borrowings and fund corporate needs.
Risk Factors
Net Income Declines Net income attributable to IQVIA Holdings Inc. fell to $846M USD for nine months, down $90M from $936M in 2024.
Segment Profit Pressure Total segment profit decreased $43M USD for nine months, reflecting margin compression across core operational areas.
Increased Cost of Revenues Cost of revenues (excl. D&A) grew 6.6% constant currency for nine months, slightly outpacing revenue growth.
Restructuring Costs Incurred $81M restructuring costs recorded for nine months due to ongoing global streamlining and capacity alignment efforts.
Outlook
Share Repurchase Authorization $13.73B total authorization; $1.98B remains available as of September 30, 2025 after $1.03B spent YTD.
Future Revenue Recognition Approximately $34.4B of revenues expected from remaining performance obligations, mostly recognized over the next five years.
Debt Maturity Management Repaid Euro denominated 2.875% Senior Notes due 2025 during the quarter, managing debt maturity profile proactively.
New Tax Disclosure Assessment Assessing impacts of ASU 2023-09 regarding income tax disclosures, effective for annual periods beginning January 1, 2025.
Peer Comparison
Revenue (TTM)
CAH$234.31B
HUM$126.36B
IQV$15.90B
Gross Margin (Latest Quarter)
86.1%
RMD61.5%
59.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CAH | $47.09B | 29.6 | -55.0% | 16.4% |
| INSM | $42.02B | -35.2 | -183.6% | 31.6% |
| A | $39.61B | 30.3 | 20.6% | 26.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
-8.8%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 5, 2026
EPS:$3.40
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 28, 2025|Revenue: $4.10B+5.2%|EPS: $1.94+23.6%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 22, 2025|Revenue: $4.02B+5.3%|EPS: $1.55-22.1%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 6, 2025|Revenue: $3.83B+2.5%|EPS: $1.42-10.1%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 13, 2025|Revenue: $15.41B+2.8%|EPS: $7.57+2.4%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $3.90B+4.3%|EPS: $1.57-5.4%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 22, 2024|Revenue: $3.81B+2.3%|EPS: $1.99+23.6%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $3.74B+2.3%|EPS: $1.58+1.3%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 15, 2024|Revenue: $14.98B+4.0%|EPS: $7.39+27.0%Miss